A detailed history of Sjs Investment Consulting Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Sjs Investment Consulting Inc. holds 6 shares of NBIX stock, worth $812. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6
Previous 9 33.33%
Holding current value
$812
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

SELL
$114.58 - $153.15 $343 - $459
-3 Reduced 33.33%
6 $0
Q2 2024

Jul 16, 2024

BUY
$130.86 - $143.19 $654 - $715
5 Added 125.0%
9 $1,000
Q4 2023

Jan 16, 2024

BUY
$106.07 - $132.76 $106 - $132
1 Added 33.33%
4 $0
Q2 2023

Jul 13, 2023

BUY
$89.53 - $104.87 $268 - $314
3 New
3 $0
Q4 2022

Jan 23, 2023

SELL
$106.72 - $127.06 $106 - $127
-1 Reduced 25.0%
3 $0
Q3 2022

Oct 13, 2022

BUY
$92.03 - $107.81 $184 - $215
2 Added 100.0%
4 $0
Q1 2022

May 05, 2022

BUY
$72.45 - $94.81 $144 - $189
2 New
2 $0

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Sjs Investment Consulting Inc. Portfolio

Follow Sjs Investment Consulting Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sjs Investment Consulting Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sjs Investment Consulting Inc. with notifications on news.